Seeking Alpha11/11/2026 19:02:12

MaxCyte outlines at least $34.5M 2026 revenue as it plans Akron Bio deal to accelerate profitability

MaxCyte outlines at least $34.5M 2026 revenue as it plans Akron Bio deal to accelerate profitability

36 min ago
View Original Source
Seeking Alpha

Seeking Alpha

Seeking Alpha is the leading platform for investors to research and discuss US-traded stocks and ETFs. Our platform helps investors to find successful investing ideas and to successfully manage their portfolios. It provides investment ideas, analysis, news, ratings, investing tools and community discussion.

More from Seeking Alpha

China Automotive Systems gives Q3 update, approves $5M buyback

16 min ago

ABN AMRO Bank N.V. (AAVMY) Q3 2026 Earnings Call Transcript

17 min ago

Spirax Group plc (SPXSY) Q3 2026 Sales/Trading Call Transcript

17 min ago

Mitsubishi Corporation: H1 Beat-And-Raise Justifies A Bullish Stance

23 min ago